Holen Sie sich die Stockscreener-App
302.12
1.04%
4.225
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt UTHR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$297.89
Offen:
$300.69
24-Stunden-Volumen:
74,383
Relative Volume:
0.14
Marktkapitalisierung:
$13.62B
Einnahmen:
$2.99B
Nettoeinkommen (Verlust:
$1.21B
KGV:
12.06
EPS:
25.06
Netto-Cashflow:
$1.13B
1W Leistung:
+0.94%
1M Leistung:
+5.09%
6M Leistung:
-19.07%
1J Leistung:
-10.62%
1-Tages-Spanne:
$299.02
$302.00
1-Wochen-Bereich:
$290.80
$302.52
52-Wochen-Spanne:
$266.98
$417.81
United Therapeutics Corp Stock (UTHR) Company Profile
Firmenname
United Therapeutics Corp
Sektor
Telefon
(301) 608-9292
Adresse
1000 SPRING ST, SILVER SPRING, MD
Vergleichen Sie UTHR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
302.00 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
|
ZTS
Zoetis Inc
|
152.28 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.74 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.75 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.59 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Hochstufung | Goldman | Sell → Neutral |
| 2024-02-05 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-06 | Eingeleitet | UBS | Buy |
| 2022-12-05 | Eingeleitet | Goldman | Sell |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-20 | Bestätigt | BofA Securities | Underperform |
| 2022-09-19 | Fortgesetzt | Wedbush | Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Neutral |
| 2021-07-14 | Hochstufung | Argus | Hold → Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-01 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-25 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-03-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-27 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-01-31 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Eingeleitet | BofA/Merrill | Underperform |
| 2019-08-01 | Hochstufung | Jefferies | Underperform → Hold |
| 2019-08-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Hochstufung | UBS | Sell → Neutral |
| 2019-05-09 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Hochstufung | Standpoint Research | Hold → Buy |
| 2018-08-08 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Bestätigt | Barclays | Underweight |
| 2018-01-18 | Fortgesetzt | Credit Suisse | Underperform |
| 2017-12-27 | Bestätigt | Wedbush | Outperform |
| 2017-04-27 | Bestätigt | Wedbush | Outperform |
| 2017-03-30 | Eingeleitet | UBS | Sell |
| 2017-03-16 | Eingeleitet | Credit Suisse | Underperform |
Alle ansehen
United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten
United Therapeutics Corporation (UTHR) Completes Phase 3 Enrollment for Promising PAH Drug Ralinepag - Insider Monkey
What analysts say about United Therapeutics Corporation stockConsistent triple returns - jammulinksnews.com
Is United Therapeutics Corporation a good long term investmentBreakthrough profit margins - jammulinksnews.com
United Therapeutics Corporation Stock Analysis and ForecastAccelerated profit realization - jammulinksnews.com
What drives United Therapeutics Corporation stock priceSkyrocketing investment returns - jammulinksnews.com
Morgan Stanley Trims United Therapeutics (UTHR) Price Target, Maintains Buy Rating - Insider Monkey
Here's Why United Therapeutics (UTHR) is a Strong Value Stock - Yahoo Finance
Pulmonary Arterial Hypertension Market Forecast 2034: - openPR.com
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages 3D Systems Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Pulmonary Arterial Hypertension Drug Market Forecast to 2032: - openPR.com
United Therapeutics Announces Q2 Earnings Date: Key Details for Biotech Investment Community - Stock Titan
Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest - Yahoo Finance
Oppenheimer Maintains United Therapeutics(UTHR.US) With Buy Rating, Cuts Target Price to $510 - 富途牛牛
Reflecting On Therapeutics Stocks' Q1 Earnings: Moderna (NASDAQ:MRNA) - FinancialContent
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
Q1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics Segment - Yahoo Finance
United Therapeutics Puts Big Bets On Tyvaso’s Trial Results - Finimize
United Therapeutics Offers Favorable Profile Ahead of Key Data, Oppenheimer Says - MarketScreener
United Therapeutics (UTHR) Awaits Key Catalyst with Positive Ris - GuruFocus
United Therapeutic's: The Brands First Hydrogen Helicopter - Energy Digital Magazine
United Therapeutics’ Phase 3 Study on Inhaled Treprostinil: A Potential Game-Changer for Pulmonary Fibrosis - TipRanks
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term - Yahoo Finance
United Therapeutics’ Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis: Key Insights for Investors - TipRanks
UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR) - Insider Monkey
United Therapeutics (UTHR) Price Target Adjustment by Morgan Sta - GuruFocus
United Therapeutics (UTHR) Price Target Trimmed by Morgan Stanle - GuruFocus
United Therapeutics' Inhaled Treprostinil Study for Pulmonary Fibrosis: Key Insights for Investors - AInvest
United Therapeutics (UTHR): JP Morgan Adjusts Price Target | UTH - GuruFocus
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
United Therapeutics Faces Key Moment With Tyvaso's Q3 Results - Finimize
United Therapeutics (UTHR) Maintains Buy Rating, Price Target Lowered by UBS | UTHR Stock News - GuruFocus
United Therapeutics’ Promising Study on Inhaled Treprostinil for Pulmonary Fibrosis - TipRanks
United Therapeutics (UTHR) Maintains Buy Rating, Price Target Lo - GuruFocus
United Therapeutics Announces World’s First Bioengineered External Liver Treatment in Clinical Study - Yahoo Finance
United Therapeutics EVP Mahon sells $3.14 million in UTHR stock - Investing.com
United Therapeutics’ Ralinepag Study: A Potential Game-Changer in PAH Treatment - TipRanks
Nilda Mesa, United Therapeutics director, sells $187k in stock - Investing.com
United Therapeutics (UTHR) Begins Groundbreaking Clinical Study with miroliverELAP | UTHR Stock News - GuruFocus
Pulmonary Arterial Hypertension Market Set to Grow Substantially Through 2034, DelveInsight Projects | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros - Barchart.com
United Therapeutics delivers 18th consecutive quarter of topline growth - MarketScreener
United Therapeutics EVP Paul Mahon sells $3.08m in stock By Investing.com - Investing.com Canada
United Therapeutics Insider Sold Shares Worth $3,079,514, According to a Recent SEC Filing - MarketScreener
United Therapeutics EVP Paul Mahon sells $3.08m in stock - Investing.com
AppLovin, Chewy And Carvana Are Among Top 11 Large Cap Losers Last Week (June 9-13): Are The Others In Your Portfolio? - Benzinga
United Therapeutics (UTHR) Soars 3.5%: Is Further Upside Left in the Stock? - Yahoo Finance
United Therapeutics (UTHR) Maintains Neutral Rating, Price Targe - GuruFocus
United Therapeutics: Tanking On Rival's PAH DataI'd Consider Buying Stock (NASDAQ:UTHR) - Seeking Alpha
Insmed Shares Rise After Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints - marketscreener.com
United Therapeutics (UTHR) Stock Plummets Over 15% in Major Sell-Off - Daily Chhattisgarh News
Liquidia, United Therapeutics fall after mid-stage data for Insmed’s PAH asset - Seeking Alpha
Treprostinil Saga Continues - JD Supra
Finanzdaten der United Therapeutics Corp-Aktie (UTHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
United Therapeutics Corp-Aktie (UTHR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Jul 10 '25 |
Sale |
300.31 |
11,000 |
3,303,394 |
36,781 |
0.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):